AU2020276296A1 - NK cell-directed chimeric proteins - Google Patents

NK cell-directed chimeric proteins Download PDF

Info

Publication number
AU2020276296A1
AU2020276296A1 AU2020276296A AU2020276296A AU2020276296A1 AU 2020276296 A1 AU2020276296 A1 AU 2020276296A1 AU 2020276296 A AU2020276296 A AU 2020276296A AU 2020276296 A AU2020276296 A AU 2020276296A AU 2020276296 A1 AU2020276296 A1 AU 2020276296A1
Authority
AU
Australia
Prior art keywords
chimeric protein
domain
nkg2a
cells
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020276296A
Other languages
English (en)
Inventor
Suresh DE SILVA
George FROMM
Taylor Schreiber
Casey SHUPTRINE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shattuck Labs Inc
Original Assignee
Shattuck Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shattuck Labs Inc filed Critical Shattuck Labs Inc
Publication of AU2020276296A1 publication Critical patent/AU2020276296A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020276296A 2019-05-16 2020-05-15 NK cell-directed chimeric proteins Abandoned AU2020276296A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962848915P 2019-05-16 2019-05-16
US62/848,915 2019-05-16
PCT/US2020/033169 WO2020232365A1 (en) 2019-05-16 2020-05-15 Nk cell-directed chimeric proteins

Publications (1)

Publication Number Publication Date
AU2020276296A1 true AU2020276296A1 (en) 2021-11-11

Family

ID=73289381

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020276296A Abandoned AU2020276296A1 (en) 2019-05-16 2020-05-15 NK cell-directed chimeric proteins

Country Status (7)

Country Link
US (2) US20200399344A1 (cg-RX-API-DMAC7.html)
EP (1) EP3969058A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022532430A (cg-RX-API-DMAC7.html)
CN (1) CN114126663A (cg-RX-API-DMAC7.html)
AU (1) AU2020276296A1 (cg-RX-API-DMAC7.html)
CA (1) CA3140055A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020232365A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119039440A (zh) * 2021-07-02 2024-11-29 来凯医药科技(上海)有限公司 活化的肝星状细胞(hsc)的消耗及其用途
CN114853905B (zh) * 2022-04-14 2022-11-22 呈诺再生医学科技(珠海横琴新区)有限公司 一种基因修饰nk细胞与抗体联合使用治疗肿瘤方案
WO2024073513A2 (en) * 2022-09-27 2024-04-04 Affini-T Therapeutics, Inc. Chimeric receptors comprising interleukin 7 receptor (il7r) domains
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932055B2 (en) * 2006-06-22 2011-04-26 Novo Nordisk A/S Soluble heterodimeric CD94/NKG2 receptors fusion proteins
US20140370012A1 (en) * 2012-01-27 2014-12-18 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
SG10201913573UA (en) * 2015-10-01 2020-03-30 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
US10906957B2 (en) * 2016-09-27 2021-02-02 Epicentrx, Inc. Immunomodulatory fusion proteins

Also Published As

Publication number Publication date
CA3140055A1 (en) 2020-11-19
US20200399344A1 (en) 2020-12-24
US20230045794A1 (en) 2023-02-16
JP2022532430A (ja) 2022-07-14
EP3969058A1 (en) 2022-03-23
WO2020232365A1 (en) 2020-11-19
CN114126663A (zh) 2022-03-01
EP3969058A4 (en) 2023-06-28

Similar Documents

Publication Publication Date Title
JP7260477B2 (ja) Tigit及びlightベースのキメラタンパク質
US20230045794A1 (en) Nk cell-directed chimeric proteins
US20200071380A1 (en) Combination therapies comprising sirp alpha-based chimeric proteins
US20220185863A1 (en) Combination therapies
CA3149583A1 (en) Chimeric proteins in autoimmunity
CN112888711A (zh) 基于flt3l的嵌合蛋白
WO2022187583A1 (en) Combination therapies with tim-3-based chimeric proteins
AU2018224852B2 (en) VSIG8-based chimeric proteins
US20240141014A1 (en) Mutant pd-1 extracellular domains
US20240299492A1 (en) Combination therapies with sirp alpha-based chimeric proteins
US20230048633A1 (en) Tgfbr2-based chimeric proteins
US20210179689A1 (en) Combination therapies comprising tim-3-based chimeric proteins
RU2792239C2 (ru) Химерные белки на основе csf1r
WO2024123890A1 (en) Methods of using light-based chimeric proteins
HK40019689B (en) Vsig8-based chimeric proteins
HK40019689A (en) Vsig8-based chimeric proteins

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period